Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Cash from Financing Activities (2021 - 2025)

Journey Medical's Cash from Financing Activities history spans 5 years, with the latest figure at $5.4 million for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities fell 48.9% year-over-year to $5.4 million, compared with a TTM value of $16.2 million through Dec 2025, down 4.51%, and an annual FY2025 reading of $16.2 million, down 4.51% over the prior year.
  • Cash from Financing Activities for Q4 2025 was $5.4 million at Journey Medical, down from $7.0 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $31.8 million in Q4 2021, with the low at -$13.1 million in Q2 2023.
  • Average Cash from Financing Activities over 5 years is $4.9 million, with a median of $3.8 million recorded in 2022.
  • Year-over-year, Cash from Financing Activities tumbled 11890.99% in 2023 and then surged 3048.08% in 2024.
  • Tracing DERM's Cash from Financing Activities over 5 years: stood at $31.8 million in 2021, then tumbled by 97.02% to $948000.0 in 2022, then surged by 1926.37% to $19.2 million in 2023, then tumbled by 44.72% to $10.6 million in 2024, then tumbled by 48.9% to $5.4 million in 2025.
  • Per Business Quant, the three most recent readings for DERM's Cash from Financing Activities are $5.4 million (Q4 2025), $7.0 million (Q3 2025), and $165000.0 (Q2 2025).